T&R Biofab Co., Ltd

As of June 30, 2026, T&R Biofab Co., Ltd carries a market capitalization of 98.22B, placing it among publicly traded companies globally. Its enterprise value stands at 122.62B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, T&R Biofab Co., Ltd has 47.56M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 2.56, and the price-to-book ratio stands at 4.63.

These figures are as of June 30, 2026. The EV/Sales ratio of 3.75 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 122.62B versus a market cap of 98.22B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, T&R Biofab Co., Ltd maintains a current ratio of 0.33, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 143.98, indicating elevated leverage, while an interest coverage ratio of -0.08 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, T&R Biofab Co., Ltd posted a negative return on equity (ROE) of -143.56, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -29.53, reflecting losses generated across the asset base. The company generates approximately 381.72M in revenue per employee across its workforce of 85.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 5.36 indicates how many times T&R Biofab Co., Ltd sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 23, 2026, T&R Biofab Co., Ltd's stock has declined approximately 82.09% over the past 52 weeks. The 50-day moving average sits at 2,268.84, while the 200-day moving average is 2,695.59.

Over the twelve months ended June 30, 2026, T&R Biofab Co., Ltd generated 32.73B in revenue and converted that into -27.71B in net income, yielding earnings per share of -683.16. EBITDA reached -517.60M, while operating income came in at -4.98B.

As of June 30, 2026, T&R Biofab Co., Ltd holds 6.13B in cash and equivalents against 30.53B in total debt, resulting in a net debt position of 23.68B. Total book value stands at 21.20B, with working capital of -36.15B providing operational flexibility.

T&R Biofab Co., Ltd produced -2.25B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -2.64B in capital expenditures, free cash flow totaled -4.89B - equivalent to -120.65 per share.

Over the twelve months ended June 30, 2026, T&R Biofab Co., Ltd posted a gross margin of 31.31, reflecting its pricing power and cost economics. The operating margin of -15.22 and net profit margin of -84.66 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -5.84: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 3.13, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to T&R Biofab Co., Ltd shareholders.

T&R Biofab Co., Ltd's most recent stock split took place on October 29, 2025 with a 5:1 split ratio.

As of June 30, 2026, T&R Biofab Co., Ltd has an Altman Z-Score of -2.15, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.